ERBB2 and breast carcinoma: The PI3K/AKT/mTOR signaling axis was chosen for investigation in this study due to its well-recognized role in regulating cell proliferation, survival, and therapy resistance in cancer, particularly in aggressive breast cancer subtypes, such as TNBC and HER2+ breast cancer [25].